1. Review the use of neoadjuvant chemotherapy for HER2 negative breast cancer
2. Identify known predictors of response to neoadjuvant therapy
3. Discuss the promise of deep learning on digital pathology as a tool to identify responders to neoadjuvant treatment
09/21/2020 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Frederick M. Howard, M.D.